{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06188702",
            "orgStudyIdInfo": {
                "id": "CL1-95035-001"
            },
            "organization": {
                "fullName": "Servier",
                "class": "INDUSTRY"
            },
            "briefTitle": "S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene",
            "officialTitle": "A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "in-adult-participants-with-advanced-or-metastatic-solid-tumors-with-deletion-of-the-methylthioadenosine-phosphorylase-mtap-gene"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-18",
            "studyFirstSubmitQcDate": "2024-01-02",
            "studyFirstPostDateStruct": {
                "date": "2024-01-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-02",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Servier Bio-Innovation LLC",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Institut de Recherches Internationales Servier",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a first-in-human Phase 1, multicenter, open-label dose escalation study of S095035 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \\[MAT2A\\] inhibitor."
        },
        "conditionsModule": {
            "conditions": [
                "MTAP-deleted Solid Tumors"
            ],
            "keywords": [
                "MAT2A",
                "MTAP",
                "Solid Tumors",
                "PRMT5",
                "SAM",
                "Synthetic Lethality",
                "MTAP deletion",
                "MAT2A Inhibitor",
                "Advanced Solid Tumors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 27,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: S095035"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "S095035",
                    "description": "S095035 will be taken orally once daily in 28-day cycle.",
                    "armGroupLabels": [
                        "Dose Escalation"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose limiting toxicities (DLTs) associated with S095035 administration during the first cycle of treatment",
                    "timeFrame": "Through cycle 1 (each cycle is 28 days)"
                },
                {
                    "measure": "Total number of adverse events (AEs)",
                    "timeFrame": "Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment)"
                },
                {
                    "measure": "Total number of serious adverse events (SAEs)",
                    "timeFrame": "Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Area under the concentration-vs-time curve (AUC) from 0 to time of last measurable concentration (AUC0-t)",
                    "timeFrame": "Through the last dose of study treatment (approximately 2 years)"
                },
                {
                    "measure": "AUC from 0 to infinity (AUC0-\u221e)",
                    "timeFrame": "Through the last dose of study treatment (approximately 2 years)"
                },
                {
                    "measure": "AUC over 1 dosing interval at steady state (AUCtau,ss)",
                    "timeFrame": "Through the last dose of study treatment (approximately 2 years)"
                },
                {
                    "measure": "Time to maximum concentration (Tmax)",
                    "timeFrame": "Through the last dose of study treatment (approximately 2 years)"
                },
                {
                    "measure": "Maximum concentration (Cmax)",
                    "timeFrame": "Through the last dose of study treatment (approximately 2 years)"
                },
                {
                    "measure": "Trough concentration (Ctrough)",
                    "timeFrame": "Through the last dose of study treatment (approximately 2 years)"
                },
                {
                    "measure": "Half-life (t\u00bd)",
                    "timeFrame": "Through the last dose of study treatment (approximately 2 years)"
                },
                {
                    "measure": "Apparent volume of distribution (Vd/F)",
                    "timeFrame": "Through the last dose of study treatment (approximately 2 years)"
                },
                {
                    "measure": "Apparent clearance (CL/F)",
                    "timeFrame": "Through the last dose of study treatment (approximately 2 years)"
                },
                {
                    "measure": "Change from baseline in plasma concentrations of S-adenosylmethionine (SAM)",
                    "timeFrame": "Through the last dose of study treatment (approximately 2 years)"
                },
                {
                    "measure": "Objective response rate",
                    "description": "Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and per the investigator's assessment",
                    "timeFrame": "Through the end of the study (approximately 2 years)"
                },
                {
                    "measure": "Clinical benefit rate (CBR)",
                    "description": "CBR=complete response \\[CR\\]+partial response \\[PR\\]+stable disease \\[SD\\] ) \u22656 months, Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and per the investigator's assessment",
                    "timeFrame": "Through the end of the study (approximately 2 years)"
                },
                {
                    "measure": "Duration of response",
                    "description": "Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and per the investigator's assessment. The time from date of first documented confirmed CR or confirmed PR to date of first documented disease progression or death due to any cause.",
                    "timeFrame": "Through the end of the study (approximately 2 years)"
                },
                {
                    "measure": "Time to response",
                    "description": "Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and per the investigator's assessment. The time from the date of randomization to date of first documented confirmed complete response (CR) or confirmed partial response (PR).",
                    "timeFrame": "Through the end of the study (approximately 2 years)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Estimated life expectancy \u22653 months.\n* ECOG PS 0-1\n* Participants able to comply with highly effective method of birth control requirements.\n* Participants with histologically confirmed advanced or metastatic solid tumor's (excluding central nervous system tumors) that have progressed despite at least one prior treatment regimen given for advanced/metastatic disease, and for whom additional effective standard therapy is not available.\n* Participants with pre-existing documented MTAP homozygous deletion in their tumor tissue, determined using a next generation sequencing in vitro diagnostic test prior to screening.\n* Participants willing to undergo paired fresh biopsy (pre-treatment and post-treatment) procedure. Exceptions may be made for feasibility and safety concerns.\n* Adequate organ functions.\n\nExclusion Criteria:\n\n* Inability to take an orally administered drug, or medical disorder or prior surgical resection that may affect the absorption of the study drug.\n* Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's Medical monitor and investigator agree and document that it should not be exclusionary.\n* Known prior severe hypersensitivity to any component of the study drug formulation.\n* Major surgery within 4 weeks prior to the first IMP administration or participants who have not recovered from side effects of the surgery.\n* Have a known history of Gilbert's syndrome.\n* Participants with a known clinically significant cardiovascular disease or condition.\n* Participants with thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to first IMP administration.\n* Active brain metastases.\n* Current active liver or biliary disease.\n* Participants who have received systemic anticancer treatment or radiotherapy less than 2 weeks before the first dose of S095035. Participants who have not recovered from toxicity of previous anticancer therapy.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department",
                    "role": "CONTACT",
                    "phone": "+33 1 55 72 60 00",
                    "email": "scientificinformation@servier.com"
                }
            ],
            "locations": [
                {
                    "facility": "Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Lake Mary",
                    "state": "Florida",
                    "zip": "32746",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.75888,
                        "lon": -81.31784
                    }
                },
                {
                    "facility": "SCRI Oncology Partners",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78758",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "Scientia Clinical Research",
                    "status": "RECRUITING",
                    "city": "Randwick",
                    "state": "New South Wales",
                    "zip": "2031",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.91439,
                        "lon": 151.24895
                    }
                },
                {
                    "facility": "The Alfred",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Prahran",
                    "state": "Victoria",
                    "zip": "3004",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.85114,
                        "lon": 144.99318
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.\n\nAccess can be requested for all interventional clinical studies:\n\n* used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).\n* where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.\n\nIn addition, access can be requested for all interventional clinical studies in patients:\n\n* sponsored by Servier\n* with a first patient enrolled as of 1 January 2004 onwards\n* for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "timeFrame": "After Marketing Authorization in EEA or US if the study is used for the approval.",
            "accessCriteria": "Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.",
            "url": "http://clinicaltrials.servier.com/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}